HOXB13 mutations in a population‐based, case–control study of prostate cancer12. Issue 6 (5th November 2012)

• Record Type: Journal Article
• Authors: Stott‐Miller, Marni; Karyadi, Danielle M.; Smith, Tiffany; Kwon, Erika M.; Kolb, Suzanne; Stanford, Janet L.; Ostrander, Elaine A.
• Is Part Of: Prostate. Volume 73:Issue 6(2013)
• Page Start: 634
• Page End: 641
• Publication Date: 2012-11-05
• Subjects: Prostate -- Diseases -- Periodicals; 616
• DOI: 10.1002/pros.22604
• Languages: English
• ISSNs: 0270-4137

Abstract

<abstract abstract-type="main" xml:lang="en"> <title>Abstract</title> <sec id="abs1-1" sec-type="section"> <title>BACKGROUND</title> <p>Prostate cancer (PC) is the most frequently diagnosed non‐skin malignancy in men in the Western world, yet few disease‐associated mutations have been found. Recently, a low frequency recurring mutation in the <italic>HOXB13</italic> gene was reported among both hereditary PC families and men from the general population.</p> </sec> <sec id="abs1-2" sec-type="section"> <title>MATERIALS AND METHODS</title> <p>We determined the distribution and frequency of the G84E <italic>HOXB13</italic> variant in 1, 310 incipient PC cases and 1, 259 age‐mated controls from a population‐based, case–control study of PC.</p> </sec> <sec id="abs1-3" sec-type="section"> <title>RESULTS</title> <p>The G84E mutation was more frequent in cases than controls (1.3% vs. 0.4%, respectively), and men with the <italic>HOXB1</italic>3 G84E variant had a 3.3‐fold higher relative risk of PC compared with noncarriers (95% CI, 1.21–8.96). There was a stronger association between the G84E variant and PC among men with no first‐degree relative with PC (OR, 4.04; 95% CI, 1.12–14.51) compared to men with a family history of PC (OR, 1.49; 95% CI, 0.30–7.50; <italic>P</italic> = 0.36 for interaction). We observed some evidence of higher risk estimates associated with the variant for men with higher versus lower Gleason score (OR, 4.13; 95% CI, 1.38–12.38 vs. OR, 2.71; 95% CI, 0.88–8.30), and advanced versus local stage (OR, 4.47; 95% CI, 1.28–15.57 vs. OR, 2.98; 95% CI, 1.04–8.49), however these differences were not statistically different.</p> </sec> <sec id="abs1-4" sec-type="section"> <title>CONCLUSIONS</title> <p>These results confirm the association of a rare <italic>HOXB13</italic> mutation with PC in the general population and suggest that this variant may be associated with features of more aggressive disease. Prostate 73: 634–641, 2013. © 2012 Wiley Periodicals, Inc.</p> </sec> </abstract>